This Focused Issue on “Oligometastasis- Fallacy or Real Deal?” is edited by Prof. Simon Lo from University of Washington School of Medicine, USA, Prof. Michael Milano from University of Rochester Medical Center, USA, Prof. Tithi Biswas from Case Western Reserve University, USA and Prof. Charles Simone from New York Proton Center, USA.
Dr. Simon S. Lo is Professor and Vice Chair for Strategic Planning of Radiation Oncology, Professor of Neurological Surgery and Director of Stereotactic Body Radiation Therapy at University of Washington Medical Center in Seattle, WA. Dr. Lo is currently the chair of the American College of Radiology-American Radium Society Appropriateness Use Committee in Bone Metastasis and the radiation oncology track co-chair for RSNA refresher course, and is an expert in brain and spinal tumors, stereotactic radiosurgery and stereotactic body radiotherapy (SBRT). He is also the President for CARROS of American College of Radiology (ACR). Dr. Lo is also on the Board of Directors of Radiosurgery Society. In 2019, he has received the Lifetime Achievement Award from Society for Palliative Radiation Oncology.
He has published over 200 peer-reviewed papers, over 50 book chapters and 4 textbooks, including a comprehensive textbook in SBRT (>50,000 downloads), in addition to an adult CNS radiation oncology textbook (>40,000 downloads) . He has given lectures on SBRT in American Society for Radiation Oncology (ASTRO), Radiological Society of North America (RSNA), Radiosurgery Society (RSS), ESTRO, International Stereotactic Radiosurgery Society (ISRS), and American Thoracic Society (ATS) conferences and in multiple US and international academic centers. He is on the editorial boards of multiple oncology journals including Neurosurgery and Advances in Radiation Oncology and also a reviewer for Lancet, Lancet Oncol, Nature Reviews Clinical Oncol, JCO, Radiotherapy & Oncol, and IJROBP.
His areas of research are in palliative radiation oncology, CNS tumors, stereotactic radiosurgery, radiobiological modeling for ablative radiotherapy, SBRT for lung, liver and spinal tumors, and toxicities associated with SBRT. He is a Fellow of American College of Radiology and American Society for Radiation Oncology (ASTRO).
Dr. Milano is an Associate Professor of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. Dr. Milano's practice focuses on the care of patients with primary brain tumors, brain metastases, spine tumors, benign intracranial tumors (such as pituitary tumors, acoustic neuromas and meningiomas) and trigeminal neuralgia. Dr. Milano also treats patients with lung cancer and other thoracic tumors, head and neck cancer and metastatic cancer. He is involved in clinical research in all of these areas.
Dr. Milano is a board certified Radiation Oncologist. His undergraduate training was at the University of Notre Dame. His medical school, graduate school and internship training were at the University of Rochester. He received his residency training in Radiation Oncology at the University of Chicago. In 2005, he returned to Rochester to become a faculty member at University of Rochester's internationally recognized Department of Radiation Oncology. Dr. Milano has clinical expertise in stereotactic radiosurgery (SRS), stereotactic body (including spine) radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), and image guided radiation therapy (IGRT) and tomotherapy.
Dr. Tithi Biswas is Associate Professor and Radiation Oncology Residency program Director at University Hospitals, Case Western Reserve University in Cleveland, OH. Dr. Biswas is currently serving as a member of the Cancer research committee, ASCO as well as History Committee in ASTRO. She also served as the member of ASCO annual meeting educational committee for 2020. She is an expert in Lung and other thoracic malignancies, breast cancer and stereotactic body radiotherapy (SBRT).
She has published 45 peer-reviewed papers, 6 book chapters and 75 abstracts. She is a reviewer for. Practical Radiation Oncology, Radiotherapy & Oncology, Cancer, Dove Medical Press, Oncotarget, PLOS one, Cancer medicine. Her areas of research are in lung cancer, triple negative breast cancer, and SBRT for lung, liver tumors, and toxicities associated with SBRT.
Charles B. Simone, II, MD, FACRO is a Research Professor and the Chief Medical Officer of the New York Proton Center and a Full Member in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He is an internationally recognized expert in the use of proton therapy to treat thoracic malignancies and for reirradiation, and in the development of clinical trial strategies and innovative research in thoracic radiation oncology and stereotactic body radiation therapy. He is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for lung cancer, malignant pleural mesothelioma, and other thoracic malignancies.
Prior to coming to NYPC, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at the University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, proton therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program. He completed his undergraduate and medical school training at the University of Pennsylvania, internship in internal medicine, and residency training in radiation oncology at the National Cancer Institute, NIH, where he served as chief resident.
Dr. Simone has published >320 peer-reviewed scientific articles and book chapters, given >200 scientific lectures to national and international audiences, and is the national Principal Investigator or Co-Chair of 7 NIH-funded cooperative group trials (4 NRG Oncology, 1 SWOG, 1 ECOG-ACRIN, 1 PCG). He is a three-time winner of the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award. Dr. Simone Chairs or Co-Chairs the Proton Collaborative Group (PCG) Executive Committee; PCG Lung Committee; American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee; ASTRO Small Cell Lung Cancer Guidelines Committee; American Radium Society-American College of Radiology (ARS-ACR) Appropriate Use Criteria Thoracic Committee; Particle Therapy Co-Operative Group (PTCOG) Gastrointestinal Subcommittee; PTCOG Skull Base/Central Nervous System, Sarcoma Subcommittee; American College of Radiation Oncology (ACRO) Recruitment Subcommittee; ACRO Annual Meeting Abstracts Committee; and National Cancer Institute/Radiosurgery Society (RSS) GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group. He is the Editor-in-Chief of Annals of Palliative Medicine and on the Editorial Boards of Journal of Clinical Oncology, Journal of Thoracic Disease, Frontiers in Oncology, Translational Lung Cancer Research, Annals of Translational Medicine, Therapeutic Radiology and Oncology, and Shanghai Chest.
Focused issue outline:
- General overview of oligometastases
- Technical factors of SBRT for the non-radiation oncologist
- Oligometastases from NSCLC
- Oligometastases from breast cancer
- Oligometastases from prostate cancer
- Oligometastases from colorectal cancer
- Oligometastases in pediatric cancers
- Limited brain metastases
- Completed and Ongoing RCTs
- Role of immunotherapy in the treatment of oligometastases
- Biologic predictors of radiation response and Genomics of oligometastases
The focused issue “Oligometastasis- Fallacy or Real Deal?” was commissioned by the editorial office, Annals of Palliative Medicine without any sponsorship or funding. Simon Lo, Michael Milano, Tithi Biswas and Charles B. Simone, II are serving as the unpaid Guest Editors for the focused issue.